Coherus Oncology
CHRS
75 hedge funds and large institutions have $435M invested in Coherus Oncology in 2015 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 32 increasing their positions, 7 reducing their positions, and 7 closing their positions.
357% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 7
343% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 7
96% more capital invested
Capital invested by funds: $222M → $435M (+$213M)
47% more funds holding
Funds holding: 51 → 75 (+24)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
33% less call options, than puts
Call options by funds: $175K | Put options by funds: $260K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$47.4M |
| 2 |
TCP
Tourbillon Capital Partners
New York
|
+$18.1M |
| 3 |
TCIM
TIAA CREF Investment Management
New York
|
+$17.8M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$15.6M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$10.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EI
EAM Investors
Solana Beach,
California
|
-$4.97M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$4.42M |
| 3 |
Millennium Management
New York
|
-$3.63M |
| 4 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$3.06M |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$1.34M |
CHRS Hedge Fund Activity: Q2 2015 in Review
75 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q2 2015, worth a combined $435M — up 96% from $222M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new CHRS positions and 7 closed out — a net gain of 24 holders — while 32 added to existing stakes and 7 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $47.4M. The largest seller was EAM Investors, exiting entirely with an estimated $4.97M sold.
- 75 institutional investors held Coherus Oncology (CHRS) as of Q2 2015, up from 51 in Q1 2015.
- Funds reported $435M of Coherus Oncology stock for Q2 2015, up 96% quarter-over-quarter.
- 31 funds opened new Coherus Oncology positions in Q2 2015 and 7 closed out, a net change of +24 holders.
- The largest Coherus Oncology buyer in Q2 2015 was Fidelity Investments, an estimated $47.4M added.
- The largest Coherus Oncology seller in Q2 2015 was EAM Investors, an estimated $4.97M sold.
Based on aggregated 13F filings for Q2 2015.